Pfizer’s COVID-19 pill appears to provide little or no benefit for younger adults. That’s according to a large study by Israeli researchers. The study of more than 100,000 patients showed the drug significantly reduced hospitalization and death among senors. But younger adults didn’t show any measurable benefit in the study, which was published last week in the New England Journal of Medicine. Fond du Lac County Public Health Officer Kim Mueller says the vast majority of individuals who end up in the hospital are of a senior age, “…where they have a little bit of those co-morbitities working against them,” Mueller told WFDL news. “If the drug did see significant or benefits to the populations that we more see in the hospital and not for the population we don’t see in the hospital than I can see how that would make sense.” The results raise questions about the U.S. government’s use of Paxlovid, which has become the go-to treatment for COVID-19. The Biden administration has spent more than $10 billion purchasing and distributing Pfizer’s drug.
